2024 ASH Posters

The molecules presented are investigational. Safety and efficacy have not been established.

BL-M11D1, a Novel CD33 Antibody-drug Conjugate (ADC), in Patients with Relapsed/refractory Acute Myeloid Myeloid Leukemia: Initial Results from a First-in-human Phase 1 Study.